Literature DB >> 32894400

Platelet count trends and response to fondaparinux in a cohort of heparin-induced thrombocytopenia suspected patients after pulmonary endarterectomy.

Ji-Feng Li1,2,3,4, Li-Juan Wu5,6, Ge-Yi Wen4, Rong-Rong Zhou4, Fang Liu7, Wei Wang4, Su-Qiao Yang1,2,3,4, Juan-Ni Gong1,2,3,4, Ran Miao2,3,4, Song Gu8, Yan Liu9, Yuan-Hua Yang10,11,12,13.   

Abstract

A definitive diagnosis of heparin-induced thrombocytopenia (HIT) is difficult to make, especially in patients undergoing cardiac surgery. In this retrospective cohort study, we assessed the platelet count trends and the response to fondaparinux in a population of patients of suspected HIT after pulmonary endarterectomy (PEA). Patients enrolled in this study were over the age of 18 years, and survived longer than 7 days after PEA between January 1, 2011 and December 31, 2015. HIT likelihood was assessed by the 4 T's score and interpreted by our institutional algorithm. 54 patients were operated, and 49 patients met the inclusion criteria. Six patients met the criteria for suspected HIT and were treated with fondaparinux until the platelet recovered. No significant difference was observed of clinical characteristics between intermediate to high HIT likelihood patients (HIT SUSPECTED) and low HIT likelihood patients (NO HIT SUSPECTED). HIT SUSPECTED patients reached platelet count lowest later (about 5.5 days after PEA), while NO HIT SUSPECTED patients is about 4.0 days after PEA. Percentage of platelet counts decrease (> 50%) was larger than NO HIT SUSPECTED patients (< 50%). There was no difference in mortality or residual pulmonary hypertension between HIT SUSPECTED and NO HIT SUSPECTED patients. Two HIT SUSPECTED patients who used heparin after PEA died, the other four survived by replacing heparin or low molecular weight heparin with fondaparinux. Suspected HIT patients should be surveilled carefully. Platelet counts trends may have some hints in the prevention of HIT. Fondaparinux may be effective for patients with suspected HIT.

Entities:  

Keywords:  Chronic thromboembolic pulmonary hypertension; Fondaparinux; Platelet count; Pulmonary endarterectomy; Thrombocytopenia

Year:  2021        PMID: 32894400     DOI: 10.1007/s11239-020-02260-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  18 in total

1.  Evaluation of a diagnostic algorithm for Heparin-Induced Thrombocytopenia.

Authors:  Maria Farm; Tamam Bakchoul; Tony Frisk; Karina Althaus; Alice Odenrick; Eva-Marie Norberg; Maria Berndtsson; Jovan P Antovic
Journal:  Thromb Res       Date:  2017-02-24       Impact factor: 3.944

Review 2.  Bleeding and thrombosis in patients with continuous-flow ventricular assist devices.

Authors:  Peter M Eckman; Ranjit John
Journal:  Circulation       Date:  2012-06-19       Impact factor: 29.690

3.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Respir J       Date:  2015-08-29       Impact factor: 16.671

Review 4.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients.

Authors:  Sixten Selleng; Kathleen Selleng
Journal:  Thromb Haemost       Date:  2016-07-14       Impact factor: 5.249

Review 6.  Chronic thromboembolic pulmonary hypertension.

Authors:  Nick H Kim; Marion Delcroix; David P Jenkins; Richard Channick; Philippe Dartevelle; Pavel Jansa; Irene Lang; Michael M Madani; Hitoshi Ogino; Vittorio Pengo; Eckhard Mayer
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 7.  Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension.

Authors:  David Jenkins
Journal:  Eur Respir Rev       Date:  2015-06

Review 8.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

9.  Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE.

Authors:  Theodore E Warkentin; Bruce L Davidson; Harry R Büller; Alexander Gallus; Michael Gent; Anthonie W A Lensing; Franco Piovella; Martin H Prins; Annelise E M Segers; John G Kelton
Journal:  Chest       Date:  2011-03-10       Impact factor: 9.410

10.  Platelet Count Trends and Prevalence of Heparin-Induced Thrombocytopenia in a Cohort of Extracorporeal Membrane Oxygenator Patients.

Authors:  Mladen Sokolovic; Alexandra K Pratt; Vladimir Vukicevic; Molly Sarumi; Laura S Johnson; Nimesh S Shah
Journal:  Crit Care Med       Date:  2016-11       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.